<DOC>
	<DOCNO>NCT00957944</DOCNO>
	<brief_summary>The major aim study investigate compare drug amount deliver body sequential application 2 rotigotine transdermal patch 2 different manufacturing site .</brief_summary>
	<brief_title>Study Healthy Volunteers Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount Body</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>healthy , white , male volunteer 18 55 year age ( inclusive ) BMI 19 28 kg/m² ( inclusive ) previous participation clinical study Rotigotine history current condition epilepsy and/or seizure know clinically relevant allergy known/suspected clinically relevant drug hypersensitivity history significant skin hypersensitivity adhesives transdermal product recently unresolved contact dermatitis history present condition atopic eczematous dermatitis , psoriasis , and/or active skin disease clinically relevant abnormality physical examination , ECG , vital sign safety laboratory examination positive HIV , hepatitis B C test positive alcohol drug test relevant hepatic renal dysfunction intake medication might interfere test drug within 2 week prior dose thickly haircovered abdomen result difficulty find appropriate patch application site</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
</DOC>